Baidu
map

Eur Heart J:先天性心脏病成人生命最后一年:死亡原因和护理模式分析

2022-08-31 MedSci原创 MedSci原创

在CHD成年患者生命终结时,大量使用了可能可以避免的重症护理。这可能意味着针对CHD成年患者的临终关怀可以得到改善。

在过去的50年里,先天性心脏病(CHD)患者的预期寿命有了相当大的增长。例如,现在患有CHD的儿童有97%长大成人,而20年前这一比例为85%。尽管有这些改善,很大一部分成年CHD患者仍然有症状,并且具有过早死亡的高风险(死亡的中位年龄仍低于50岁)。长期后遗症,如心力衰竭和心律失常,随着患者年龄的增长越来越频繁,对生活质量和总生存期产生负面影响。为了了解成年CHD患者的死亡轨迹,需要进一步调查其生命的最后一年。

近日,心血管领域权威杂志Eur Heart J上发表了一篇研究文章,研究人员旨在(i)明确CHD患者的死亡原因,(ii)描述成年CHD患者生命最后一年的医疗资源使用模式。

这项回顾性死亡率随访研究使用了来自BELCODAC的医疗保健索赔和临床数据,其中包括来自比利时的CHD患者。医疗保健利用包括心血管手术、CHD专科就诊、全科医生就诊、住院、急诊(ED)就诊、入住重症监护病房(ICU)和专科姑息治疗,并使用代码进行识别。

在纳入的390名患者中,几乎有一半(45%)的研究人群死于心血管疾病。在生命的最后一年,87%的患者住院,78%的患者去了急诊科,19%的患者住进了ICU。17%的患者接受了专科姑息治疗,而现定于因心血管原因死亡的患者时只有4%的患者接受了专科姑息治疗。

由此可见,在CHD成年患者生命终结时,大量使用了可能可以避免的重症护理。这可能意味着针对CHD成年患者的临终关怀可以得到改善。未来的研究应该根据病人的需求和偏好进一步研究临终关怀的提供方式,以及医疗系统如何充分响应CHD患者需求。

原始出处:

Liesbet Van Bulck,et al.Last year of life of adults with congenital heart diseases: causes of death and patterns of care.European Heart Journal.2022.https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac484/6676419

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903539, encodeId=4841190353912, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Fri Mar 31 06:40:33 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357977, encodeId=7814135e97706, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369607, encodeId=45e2136960e73, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563659, encodeId=439e156365997, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1903539, encodeId=4841190353912, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Fri Mar 31 06:40:33 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357977, encodeId=7814135e97706, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369607, encodeId=45e2136960e73, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563659, encodeId=439e156365997, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-31 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1903539, encodeId=4841190353912, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Fri Mar 31 06:40:33 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357977, encodeId=7814135e97706, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369607, encodeId=45e2136960e73, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563659, encodeId=439e156365997, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1903539, encodeId=4841190353912, content=<a href='/topic/show?id=c8aa6335ed5' target=_blank style='color:#2F92EE;'>#死亡原因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63357, encryptionId=c8aa6335ed5, topicName=死亡原因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570c172, createdName=tigerlr98, createdTime=Fri Mar 31 06:40:33 CST 2023, time=2023-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357977, encodeId=7814135e97706, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369607, encodeId=45e2136960e73, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563659, encodeId=439e156365997, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 31 09:40:33 CST 2022, time=2022-08-31, status=1, ipAttribution=)]
    2022-08-31 slcumt

相关资讯

Nature:对先天性心脏病进展的新认识为改善治疗方案打开了大门

这项研究的结果不仅为开发CHD的个性化治疗提供了新的路线图,而且还为科学界提供了稀有的小儿心脏样本的重要资源,可用于进一步发现并加深人们对CHD的理解。

JAHA:围手术期代谢产物与先天性心脏病新生儿不良手术结局相关

在新生儿心脏手术中,围手术期代谢产物与术后结局和改善的临床模型结局相关。仅术前代谢物水平可改善风险模型,并为优化围手术期治疗提供了依据。

CTM:复旦大学黄国英/马端团队发现先天性心脏病新易感基因

通过全外显子组关联分析结合多重 PCR 靶向测序,在大样本散发 CHD 病例中发现 WDR62 具有较高的变异频率;体内外实验证实 WDR62 缺陷通过影响细胞周期和纺锤体组装抑制心肌细胞增殖。

《先天性心脏病外科治疗中国专家共识》述评

《先天性心脏病外科治疗中国专家共识》这一系列著作的出版无疑为业界直面挑战、解决问题提供了理论上的指导和行动上的规范,为整体救治水平的提升提供了路径和指南。

AIM:黄国英/严卫丽团队首次阐明母亲围孕期红细胞叶酸对子代先心病的保护作用

先天性心脏病(congenital heart disease,下称先心病)是最常见的出生缺陷,在活产新生儿中的发病率超过8‰[1],是5岁以下儿童重要死因之一[2]。黄国英团队于201

ARD:辅助素(Auxilin)是一种新型的先天性心脏传导阻滞易感基因,直接影响胎儿心脏功能

该研究将辅助素确定为新生儿红斑狼疮调节心脏功能的第一个遗传易感因子,为开发先天性心脏传导阻滞筛查和治疗策略开辟了新途径。

Baidu
map
Baidu
map
Baidu
map